Next, to explore whether targeting PLK1 can improve the sensitivity of ESCC with high expression of HN1L to chemotherapy drugs, KYSE30 cell with HN1L overexpression was injected subcutaneously into nude mice and treated with BI-2536 (5 mg/kg) and Docetaxel (3 mg/kg). Here, PLK1 is linked to esophageal squamous cell carcinoma.